MIT tech review says Sangamo found BLC11A target crispr patent | SGMO Message Board Posts


Sangamo Therapeutics, Inc.

  SGMO website

SGMO   /  Message Board  /  Read Message

 

 






Keyword
Subject
Between
and
Rec'd By
Authored By
Minimum Recs
  
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board
Msg  177113 of 178390  at  12/7/2023 3:46:26 PM  by

gg100


 In response to msg 177109 by  gomasna
view thread

Re: MIT tech review says Sangamo found BLC11A target crispr patent

 wow that's an interesting find. it seems crspr therapeutics and vertex have already made a financial contract to use Sangamo's bcl11a patent, although the article seems to suggest crspr/vertex has made a contract with Boston Children's Hospital and not necessarily Sangamo.
 
I have always wondered whether Sangamo's BCL11A knockout patent could be enforced against anyone. What if you knockout at a gene locus different that the locus that Sangamo knocked out at? i wondered also that crspr/vertex should have an obviousness defense to any sangamo patent enforcement attempt. isn't it totally obvious to all the gene engineers that knocking out the gene will stop the protein production?
 
do any of these gene knockout patents have any value? 
 
Well i guess the bcl11a knockout does. Maybe because "...the companies tried to develop an alternative—a different, nearby edit—but hadn’t been successful"?
 
But if that value was significant to sangamo, you would think that sangamo would have said something. 


     e-mail to a friend      printer-friendly     add to library      
|  
Recs: 0  
   Views: 0 []
Previous Message  Next Message    Post Message    Post a Reply return to message boardtop of board

Replies
Msg # Subject Author Recs Date Posted
177114 Re: MIT tech review says Sangamo found BLC11A target crispr patent nightowl 0 12/7/2023 3:58:00 PM




Financial Market Data provided by
.
Loading...